Biomm S.A.

Equities

BIOM3

BRBIOMACNOR2

Biotechnology & Medical Research

Market Closed - Sao Paulo Other stock markets 01:37:53 01/06/2024 am IST			5-day change	1st Jan Change
17.5 ^BRL	+6.97%		+33.49%	+202.77%

16/05	Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
18/04	Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	MT

Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 14, 2021

Biomm S.A. Announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was BRL 13.309 million compared to BRL 8.936 million a year ago. Operating loss was BRL 14.769 million compared to BRL 12.083 million a year ago. Net loss was BRL 19.529 million compared to BRL 19.608 million a year ago.

Latest news about Biomm S.A.

Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18/04	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17/04	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar	16/23/16	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	26/22/26	CI
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil	06/21/06	MT
Biomm S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days	27/21/27	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications	07/21/07	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	26/21/26	CI
Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil	17/20/17	CI
MannKind Corporation and BIOMM SA Announce that Afrezza® (insulin human) Inhalation Powder has Been Registered by the Brazilian Health Regulatory Agency	03/19/03	CI
MannKind Corporation and Biomm Enter into Distribution Agreement for Afrezza in Brazil	01/17/01	CI
Biomm S.A.(BOVESPA:BIOM3) added to Brazil Special Tag Along Stock Index	05/14/05	CI
Biomm S.A. announced that it has received BRL 10.81 million in funding from BDMGTEC SA, BNDES Participações S/A - BNDESPAR, Tekbio Fundo de Investimento em Participacoes, TMG Partners, LLC, TMG Servicos de Gestao Ltda., and other investors.	04/14/04	CI

Chart Biomm S.A.

Duration

Period

More charts

Company Profile

Biomm SA, formerly Savicevic Participacoes SA, is a Brazil-based company primarily engaged in the biotechnology industry. The Company is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Companyâs technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Companyâs technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Companyâs subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOMM S.A.	+202.77%	423M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs